Gratus Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Gratus Capital’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,000	Closed	-$32K	–	183
2018 Q1	$32K	Sell	11,000 -2,000	-15%	-$5.46K	﹤0.01%	172
2017 Q4	$36K	Hold	13,000	–	–	﹤0.01%	181
2017 Q3	$44K	Hold	13,000	–	–	0.01%	183
2017 Q2	$32K	Hold	13,000	–	–	﹤0.01%	183
2017 Q1	$30K	Hold	13,000	–	–	﹤0.01%	175
2016 Q4	$28K	Hold	13,000	–	–	﹤0.01%	178
2016 Q3	$44K	Buy	+13,000	New	+$41.3K	0.01%	175

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Gratus Capital's PDLI Position: Q2 2018 in Review

Gratus Capital sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 11,000 shares — an estimated $32K sold.

Gratus Capital first reported a position in PDLI in Q3 2016 and held it in 7 quarters. The position peaked at $44K in Q3 2017. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Gratus Capital reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Gratus Capital sold 11,000 PDL BioPharma, Inc. shares in Q2 2018, an estimated $32K.
Gratus Capital first reported a position in PDL BioPharma, Inc. in Q3 2016 and held it in 7 quarters.
Gratus Capital's PDL BioPharma, Inc. position peaked at $44K in Q3 2017.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Gratus Capital's 13F filing for Q2 2018, filed 13 Aug 2018.